Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results
Accelerate Diagnostics (NASDAQ: AXDX) has announced a conference call scheduled for Thursday, November 7, 2024, at 4:30 p.m. Eastern Time to review their 2024 third quarter results. The call will be accessible via audio webcast at ir.axdx.com, with a replay available for 30 days. Participants can join by phone at +1.877.883.0383 (US) or +1.412.902.6506 (International) using Elite Entry Number 1269422. A telephone replay will be available until November 28, 2024.
Accelerate Diagnostics (NASDAQ: AXDX) ha annunciato una videochiamata programmata per giovedì 7 novembre 2024, alle 16:30 ora orientale, per esaminare i risultati del terzo trimestre 2024. La chiamata sarà accessibile tramite webcast audio su ir.axdx.com, con una riproduzione disponibile per 30 giorni. I partecipanti possono unirsi telefonicamente al numero +1.877.883.0383 (US) o +1.412.902.6506 (Internazionale) utilizzando il Numero di Accesso Elite 1269422. Una riproduzione telefonica sarà disponibile fino al 28 novembre 2024.
Accelerate Diagnostics (NASDAQ: AXDX) ha anunciado una llamada en conferencia programada para el jueves 7 de noviembre de 2024, a las 4:30 p.m. hora del este, para revisar sus resultados del tercer trimestre de 2024. La llamada será accesible a través de un webcast de audio en ir.axdx.com, con una repetición disponible durante 30 días. Los participantes pueden unirse por teléfono al +1.877.883.0383 (EE.UU.) o al +1.412.902.6506 (Internacional), utilizando el Número de Entrada Elite 1269422. Una repetición telefónica estará disponible hasta el 28 de noviembre de 2024.
Accelerate Diagnostics (NASDAQ: AXDX)는 2024년 11월 7일 목요일 오후 4시 30분 동부 표준시로 예정된 컨퍼런스 콜을 발표했습니다. 이번 통화는 2024년 3분기 실적을 검토하기 위한 것입니다. 통화는 ir.axdx.com에서 오디오 웹캐스트를 통해 접근 가능하며, 30일 동안 다시 들을 수 있습니다. 참가자들은 +1.877.883.0383 (미국) 또는 +1.412.902.6506 (국제)로 전화에 참여할 수 있으며, Elite Entry Number 1269422를 사용해야 합니다. 전화 재생은 2024년 11월 28일까지 가능합니다.
Accelerate Diagnostics (NASDAQ: AXDX) a annoncé un appel de conférence prévu pour le jeudi 7 novembre 2024, à 16h30, heure de l'Est, pour examiner leurs résultats du troisième trimestre 2024. L'appel sera accessible via un webcast audio sur ir.axdx.com, avec une rediffusion disponible pendant 30 jours. Les participants peuvent rejoindre par téléphone au +1.877.883.0383 (USA) ou au +1.412.902.6506 (International) en utilisant le Numéro d'Accès Elite 1269422. Une rediffusion téléphonique sera disponible jusqu'au 28 novembre 2024.
Accelerate Diagnostics (NASDAQ: AXDX) hat einen Telefonkonferenz für Donnerstag, den 7. November 2024, um 16:30 Uhr Eastern Time angesetzt, um die Ergebnisse des dritten Quartals 2024 zu überprüfen. Die Konferenz ist über einen Audio-Webcast auf ir.axdx.com zugänglich, und eine Aufzeichnung ist für 30 Tage verfügbar. Teilnehmer können telefonisch unter +1.877.883.0383 (USA) oder +1.412.902.6506 (international) beitreten, indem sie die Elite-Zugangsnummer 1269422 verwenden. Eine telefonische Wiederholung ist bis zum 28. November 2024 verfügbar.
- None.
- None.
To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days.
To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 1269422. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference.
A replay of the call will be available by telephone at +1.877.344.7529 (
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. In addition to the Accelerate Arc system, the Accelerate Pheno system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA-cleared Accelerate Pheno system and Accelerate PhenoTest BC kit fully automate sample preparation, identification and phenotypic antibiotic susceptibility testing in approximately seven hours directly from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier. The FDA-cleared Accelerate Arc and BC kit platform is an automated positive blood culture sample preparation platform for use with Bruker's MALDI Biotyper® CA System (MBT-CA System) and MBT-CA Sepsityper® software extension.
© Copyright 2024 Accelerate Diagnostics, Inc. All Rights Reserved. The "ACCELERATE DIAGNOSTICS," "ACCELERATE PHENO," "ACCELERATE PHENOTEST," "ACCELERATE ARC" and "ACCELERATE WAVE" diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc. All other trademarks are the property of their respective owners.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2024-third-quarter-results-302287696.html
SOURCE Accelerate Diagnostics, Inc.
FAQ
When is Accelerate Diagnostics (AXDX) Q3 2024 earnings call?
How can I listen to Accelerate Diagnostics (AXDX) Q3 2024 earnings call?